Temocillin

Phase 3Small molecule

AAssistance Publique - Hôpitaux de Paris

Temocillin is one of 6 small molecule programs targeting Infections. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

InfectionsNot yet recruiting

PK/PDUnknown status

InfectionsPhase 3

Not yet recruiting

PK/PDPreclinical

Unknown status

Competition

Competitive Landscape

6 competitors in Infections

#DrugCompanyPhaseTrials

Invanz

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Approved

2 2

Temocillin

AAssistance Publique - Hôpitaux de Paris

Phase 3

1 3

Pentaglobin

MMedical University of Vienna

Phase 2

1 4

HLA-Matched Vsts

BBaylor College of Medicine

Phase 1

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2028

Phase 3Not yet recruiting

Infections

NCT07631364

Clinical

Trials by Indication[1]

Urinary Tract Infection4 trials

Disturbance of the Intestinal Microbiota by Temocillin vs Cefotaxime in Treatment of Febrile Urinary Tract Infections

Completed·HHåkan Hanberger·Phase 4·NCT02959957·157 enrolled

Temocillin Versus a Carbapenem as Initial Intravenous Treatment for ESBL Related Urinary Tract Infections

Completed·AAssistance Publique - Hôpitaux de Paris·Phase 3·NCT03543436·29 enrolled

Temocillin Use in Complicated Urinary Tract Infections Due to Extended Spectrum Beta-Lactamases (ESBL)/AmpC Enterobacteriaceae

Withdrawn·BBelpharma s.a.·Phase 4·NCT01543347

Show 1 more trial

Efficacy of Temocillin in Urinary Tract Infection Due to ESBL Producing and AmpC Hyperproducing Enterobacteriaceae

Unknown status·UUniversity Hospital, Grenoble·Phase 4·NCT02681263·25 enrolled

Tics1 trial

Temocillin Pharmacokinetics in Paediatrics

Unknown status·UUniversité Catholique de Louvain·Phase 4·NCT02260102·45 enrolled

Treatment1 trial

Temocillin vs Meropenem for the Targeted Treatment of Bacteraemia Resistant to Third Gen Cephalosporins

Completed·FFundación Pública Andaluza para la gestión de la Investigación en Sevilla·Phase 3·NCT04478721·334 enrolled

PK/PD1 trial

Plasma Protein Binding and PK/PD of Total and Unbound Temocillin Non-ICU Patients

Unknown status·—·N/A·NCT03557840·60 enrolled

Infections1 trial

Efficacy of Temocillin Compared to Standard of Care in the Treatment of Neisseria Gonorrhoeae Infections : A Multicenter Randomized Controlled Non-Inferiority Trial

Not yet recruiting·AAssistance Publique - Hôpitaux de Paris·Phase 3·NCT07631364·360 enrolled

Sources

References

[1]
ClinicalTrials.gov — 8 trial records for Temocillin. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Temocillin compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Temocillin. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Assistance Publique - Hôpitaux de Paris company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: AAssistance Publique - Hôpitaux de Paris

Temocillin

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2028

Trials by Indication[1]

Urinary Tract Infection4 trials

Tics1 trial

Treatment1 trial

PK/PD1 trial

Infections1 trial

References

Drug Info

Quick Facts

Related News